About sgcystine

This author has not yet filled in any details.
So far sgcystine has created 7 blog entries.

α-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases

By |2021-03-26T15:43:59-07:00March 26th, 2021|

α-Lipoic Acid (ALA) Improves Cystine Solubility in Cystinuria: Report of 2 Cases Cystinuria is an autosomal recessive disorder characterized by excessive urinary excretion of cystine, resulting in recurrent cystine kidney stones, often presenting in childhood. Current treatment options for cystinuria include dietary and/or fluid measures and potassium citrate to reduce cystine excretion and/or [...]

2020 – Update on cystine stones: current and future concepts in treatment

By |2020-12-18T11:36:38-08:00December 18th, 2020|

2020 - Update on cystine stones: current and future concepts in treatment Visit the IRDR site and original article here Download PDF Here Summary Cystine stones are relatively uncommon compared with other stone compositions, constituting just 1% to 2% of adult urinary tract stone diseases, and accounting for up to 10% of pediatric [...]

Dr Goldfarb on Corona Virus

By |2020-08-10T19:31:22-07:00August 10th, 2020|

Coronavirus News: COVID-19 increases urgency for Tablo Hemodialysis Systems "We think 30% of ICU patients are developing acute kidney injury," said Dr. David Goldfarb, Chief of Nephrology at New York Harbor VA Medical Center. Dr. Goldfarb said he could not predict this kind of system failure that occurred with patients infected with the [...]

New Formulation of Tiopronin Receives FDA Approval for Treatment of Cystinuria

By |2020-08-10T19:14:35-07:00August 10th, 2020|

New Formulation of Tiopronin Receives FDA Approval for Treatment of Cystinuria Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria, a rare inherited disorder that causes a buildup of cystine levels in the urine, resulting in [...]

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets

By |2020-10-26T07:40:27-07:00June 10th, 2019|

Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment of cystinuria, a [...]

Go to Top